<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011072</url>
  </required_header>
  <id_info>
    <org_study_id>FIR HD</org_study_id>
    <nct_id>NCT04011072</nct_id>
  </id_info>
  <brief_title>Far Infrared Therapy on Arteriovenous Fistulas in Hemodialysis Patients</brief_title>
  <official_title>Effect of Far Infrared Therapy on Arteriovenous Fistulas Maturation, Survival and Stenosis. A Randomized, Controlled Open-labeled Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holbaek Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of hemodialysis patients in the world are increasing. In order to receive a&#xD;
      sufficient dialysis, the patients needs a well functioning and stable vascular access -&#xD;
      preferably an arteriovenous fistula (AVF). Unfortunately, the AVF has a high incidence of&#xD;
      stenosis with percutaneous trans luminal angioplasty (PTA) as the only treatment option and a&#xD;
      short lifetime. Little do we know of how to improve the survival of the AVF.&#xD;
&#xD;
      With this study we want to explore the effect of far infrared therapy on the stenosis,&#xD;
      maturation and survival of the arteriovenous fistula.&#xD;
&#xD;
      The investigators will divide the patients into 2 groups: A treatment group and a control&#xD;
      group.&#xD;
&#xD;
      The treatment group will receive infrared therapy on their fistula during their dialysis&#xD;
      session. The control group will not receive any infrared therapy.&#xD;
&#xD;
      The investigators hope to reduce the risk of stenosis in the fistula and improve the fistula&#xD;
      survival with this treatment.&#xD;
&#xD;
      Furthermore, the investigators want to explore the change in several biochemical markers&#xD;
      during the treatment with infrared therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      The number of hemodialysis patients in the world are increasing. In order to receive an&#xD;
      efficient dialysis, the patient needs a well-functioning and stable vascular access.&#xD;
      Presently there is three options: an arteriovenous fistula (AVF), an arteriovenous graft&#xD;
      (AVG) and a central venous catheter (CVC). CVCs are associated with an increased risk of&#xD;
      stenosis of the central vessels, thrombosis in the AVF, infections and death. AVGs are&#xD;
      associated with increased risk of infections, stenosis in the AVG and loss of access. This is&#xD;
      why, the AVF is the preferred vascular access. But this vascular access does not come without&#xD;
      risks. After the creation of an AVF there is a risk of 50 % for never maturing, which means&#xD;
      the AVF cannot be used. Furthermore, the risk of stenosis in the AVF is also high, up to 67 %&#xD;
      of the AVFs will have a stenosis, that needs an intervention. During this time the patient&#xD;
      needs an alternative vascular access, such as a central venous catheter, which is related to&#xD;
      an increased risk of infection, more hospital days and death.&#xD;
&#xD;
      The maturation of the AVF depends on several patient related, but also surgically related&#xD;
      factors. Factors such as comorbidity, female sex, length of end stage renal disease, anatomy&#xD;
      of the vessel, surveillance after AVF placement and the operations itself have all been shown&#xD;
      to affect the AVF maturation. Fistula stenosis emerges from an endothelial dysfunction,&#xD;
      inflammation and smooth muscle cell proliferation leading to intimal hyperplasia and in the&#xD;
      end stenosis. Factors such as increased blood flow, inflammation, uremia and percutaneous&#xD;
      transluminal angioplasty has been shown to affect the stenosis, It is not well understood,&#xD;
      which molecular mechanism are responsible for the intimal hyperplasia.&#xD;
&#xD;
      There are few and not well established studies on how to improve the AVF survival and&#xD;
      maturation.&#xD;
&#xD;
      Far infrared radiation (FIR) is an electromagnetic radiation (heat therapy), that is given&#xD;
      directly on the skin above the AVF. In a few single center studies in Taiwan it has been&#xD;
      shown to decrease the risk of stenosis and increase the fistula survival and maturation.&#xD;
      However another study is disputing this. The mechanism behind FIR and better fistula survival&#xD;
      is not fully understood. The infrared light is supposed to have a thermal effect, which leads&#xD;
      to vasodilatation and a non-thermal effect, which influence the endothelial function and&#xD;
      vasodilation and thereby it may decrease the inflammation and proliferation in the fistula,&#xD;
      primarily through the releasing of several anti-inflammatory and vasodilating factors. This&#xD;
      is not well documented.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Treatment with FIR for 40 minutes three times a week on the patients AVF will improve the AVF&#xD;
      survival and maturation&#xD;
&#xD;
      Method:&#xD;
&#xD;
      This study is a randomized, controlled multicenter study on western patients&#xD;
&#xD;
      There will be 2 patient categories:&#xD;
&#xD;
        1. A group (82 patients) of dialysis patients with a newly created AF&#xD;
&#xD;
        2. A group (104 patients) of dialysis patients with an existing AVF&#xD;
&#xD;
      The patients will randomly be randomized 1:1 to either the treatment group or a control&#xD;
      group. For group 2 the patients will be block randomized according to their access flow (AF)&#xD;
      (above or below 950 ml/min). Furthermore these patients will be stratified according to&#xD;
      interventions in there AVF (no interventions &gt;/= 1 intervention) For the FIR treatment Ws Far&#xD;
      Infrared Therapy Unit, model TY-102F (Medical device Class 11a CE0434) is being used. The&#xD;
      patients will receive 40 minutes of infrared radiation on the skin of their fistula during&#xD;
      each dialysis treatment for one year. The control group will not receive any FIR treatment,&#xD;
      but will be followed according to the protocol and in line with the treatment group.&#xD;
&#xD;
      The patients will be followed until end of study or lost-to-follow-up (death,&#xD;
      transplantations, change of renal replacement therapy, abandoned AVF, change of vascular&#xD;
      access to CVC, consent withdrawal or if the patients moves away).&#xD;
&#xD;
      In order to explore the long term effects of FIR the patients will be followed for an extra 6&#xD;
      months according to the endpoints. In a subset of 2x20 patients of the randomized controlled&#xD;
      trial we further wish to explore the influence of infrared therapy on endothelial function&#xD;
      and inflammation during a FIR treatment session. Blood samples will be collected before and&#xD;
      immediately after infrared treatment directly from the treatment site, since 2 needles are&#xD;
      placed in the fistula during the dialysis treatment. The same samples will be collected in&#xD;
      the control group and in the intervention group during the dialysis before the first infrared&#xD;
      intervention in order to reduce the interindividual variation in the biomarkers.The changes&#xD;
      in markers of endothelial dysfunction and inflammation during treatment and control dialysis&#xD;
      session will be examined and compared.&#xD;
&#xD;
      Furthermore a blood sample from each patient will be collected at study start. The predictive&#xD;
      value of the biomarkers of endothelial dysfunction and inflammation for the treatment&#xD;
      response to infrared therapy and the prognosis for fistula maturation, stenosis and survival&#xD;
      will be evaluated after the randomised controlled trial has ended.&#xD;
&#xD;
      Arterial stiffness (measured by Mobil-O-Graph) will also be evaluated as a marker for fistula&#xD;
      survival and maturation.&#xD;
&#xD;
      A total of 186 participants will be recruited from 9 dialysis centres. If the study shows&#xD;
      positive results, the implication of FIR in the clinic will have a huge beneficial effect for&#xD;
      the hemodialysis patients vascular access and perhaps also patient survival. FIR is an easy&#xD;
      treatment with a low cost-effectiveness and minimal or no side effects for the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to fistula maturation for the incident fistulae</measure>
    <time_frame>After 12 months</time_frame>
    <description>Time from placement of the fistula to successful cannulation with 2 needles and successful hemodialysis treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in number of fistula intervention for the prevalent fistulae</measure>
    <time_frame>After 12 months</time_frame>
    <description>For the fistulae with or without previous interventions we expect to find a decrease in the number of interventions in the treatment group compared to the control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in number of fistula interventions in the incident fistula group</measure>
    <time_frame>After 12 months</time_frame>
    <description>Difference in the number of fistula intervention in the groups with a newly places fistula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the fistula diameter in the incident fistula group</measure>
    <time_frame>After 12 months</time_frame>
    <description>Is there a difference in the diameter measured by ultrasound between the 2 groups with patients with a newly places fistula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of abandoned fistulae in incident and prevalent groups</measure>
    <time_frame>After 12 months</time_frame>
    <description>For patients with a new fistula and patients with a fistula with/without interventions how many will loose their fistula and receive a new vascular access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of primary patency in the incident group</measure>
    <time_frame>After 12 months</time_frame>
    <description>How many of the fistulas in the group with a new fistula needs an intervention in order to get a functioning fistula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a never functioning fistula in the incident group</measure>
    <time_frame>After 12 months</time_frame>
    <description>How many patients in the newly places fistula group will never have a functioning fistula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in access flow in the incident and prevalent group</measure>
    <time_frame>After 12 moths</time_frame>
    <description>Does the access flow change between the control and treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline value in serum amyloid A as a predictor for AVF survival and stenosis</measure>
    <time_frame>After 12 months</time_frame>
    <description>Before study start the following markers will be explored : Serum Amyloid A (in Ug/ml),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline value in adhesion molecules, heme-oxygenase and ADMA and selectin as a predictor for AVF survival stenosis</measure>
    <time_frame>After 12 months</time_frame>
    <description>Before study start the following change in markers will be explored: vascular cell adhesion molecule (in ng/ml), intercellular adhesion molecule (in ng/ml), sE-selectin (in ng/ml), assymetric dimethylarginine (in ng/ml), heme-oxygenase-1 (in ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline value in von willebrand factor as a predictor for AVF survival stenosis</measure>
    <time_frame>After 12 months</time_frame>
    <description>Before study start the following change in markers will be explored: vWF in ml-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline in nitrite and nitrate as a predictor for AVF survival stenosis</measure>
    <time_frame>After 12 months</time_frame>
    <description>Before study start the following change in markers will be explored: nitrite (in uM), nitrate (in uM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline in different biomarkers as a predictor for AVF survival stenosis</measure>
    <time_frame>After 12 months</time_frame>
    <description>Before study start the following change in markers will be explored: endothelin (in pg/ml), prostaglandin E2 (in pg/ml, Interleukin-beta (pg/ml), Interleukin-6 (in pg/ml), Interleukin-8 (in pg/ml), tumor necrosis factor-alpha (in pg/ml), transformin growth factor-beta (in pg/ml) and monocyte chemoattractant protein 1 (in pg/ml).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference in cannulation pain in the incident and prevalent group compared with visual analogue scale</measure>
    <time_frame>After 12 months</time_frame>
    <description>Do the patients receiving FIR treatment experience less pain during cannulation compared to the control group evaluated by the VAS (visual analogue scale) score</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in number with steal symptoms in the incident and prevalent group</measure>
    <time_frame>After 12 months</time_frame>
    <description>Is there a difference in patients with steal symptoms in the two groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute changes in serum amyloid A after a single FIR treatment</measure>
    <time_frame>After 40 minutes of FIR treatment</time_frame>
    <description>In a subgroup of patients we want to study the acute changes of the following markers during a FIR treatment Analysing Serum Amyloid A (in Ug/ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute changes in adhesion molecules, heme-oxygenase and ADMA and selectin as a predictor for AVF survival stenosis after a single FIR treatment</measure>
    <time_frame>After 40 minutes of FIR treatment</time_frame>
    <description>In a subgroup of patients we want to study the acute changes of the following markers during a FIR treatment, analysing: vascular cell adhesion molecule (in ng/ml), intercellular adhesion molecule (in ng/ml), sE-selectin (in ng/ml), assymetric dimethylarginine (in ng/ml), heme-oxygenase-1 (in ng/ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute changes in von willebrand factor after a single FIR treatment</measure>
    <time_frame>After 40 minutes of FIR treatment</time_frame>
    <description>In a subgroup of patients we want to study the acute changes of the following markers during a FIR treatment Analysing: von WillebrandFactor (in ml-1)</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute changes in nitrite and nitrate after a single FIR treatment</measure>
    <time_frame>After 40 minutes of FIR treatment</time_frame>
    <description>In a subgroup of patients we want to study the acute changes of the following markers during a FIR treatment Analysing: nitrite (in uM), nitrate (in uM)</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute changes in different biomarkers after a single FIR treatment</measure>
    <time_frame>After 40 minutes of FIR treatment</time_frame>
    <description>In a subgroup of patients we want to study the acute changes of the following markers during a FIR treatment Analysing: endothelin (in pg/ml), prostaglandin E2 (in pg/ml), Interleukin-beta (pg/ml), Interleukin-6 (in pg/ml), Interleukin-8 (in pg/ml), tumor necrosis factor-alpha (in pg/ml), transformin growth factor-beta (in pg/ml) and monocyte chemoattractant protein 1 (in pg/ml).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">187</enrollment>
  <condition>Arterio-venous Fistula</condition>
  <arm_group>
    <arm_group_label>Infrared treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Far infrared radiation will be given for 40 minutes on the skin above the patients fistula in each dialysis session for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will not receive any intervention, but will be followed with the same data as the treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Far infrared radiation</intervention_name>
    <description>The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.</description>
    <arm_group_label>Infrared treatment arm</arm_group_label>
    <other_name>FIR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For incident AVF:&#xD;
&#xD;
          -  Patients of 18 years of age or above&#xD;
&#xD;
          -  Patients on chronic hemodialysis with a central venous catheter, who is having an AVF&#xD;
             placed&#xD;
&#xD;
          -  An AVF, that are maximum 3 weeks old&#xD;
&#xD;
        For prevalent AVF:&#xD;
&#xD;
          -  Patients in chronic hemodialysis with a functioning AVF&#xD;
&#xD;
          -  Patients of 18 yeas of age or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not obtainable informed consent&#xD;
&#xD;
          -  Non compliant patients&#xD;
&#xD;
          -  Patients who use both a CVC and an AVF as their vascular access&#xD;
&#xD;
          -  Patient on both hemodialysis and peritoneal dialysis&#xD;
&#xD;
          -  Planned living donor kidney transplantation&#xD;
&#xD;
          -  Short life expectancy, less than a 1 year&#xD;
&#xD;
          -  Patients on hemodialysis less than 3 times per week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ditte Hansen, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Herlev Hospital, Department of Nephrology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristine Lindhard, Doctor</last_name>
    <phone>+4538681977</phone>
    <email>kristine.lindhard.rasmussen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ditte Hansen, Doctor</last_name>
    <phone>+45 3868</phone>
    <email>ditte.hansen.04@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ylian Liam, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Lindhard, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hilleroed Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Berthelsen, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristine Hommel, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Lindhard, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne Rix, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nykøbing Falster Hospital</name>
      <address>
        <city>Nykøbing Falster</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirstine Gliese, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirstine Gliese, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristine Hommel, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Lacson E Jr, Wang W, Hakim RM, Teng M, Lazarus JM. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis. 2009 Jan;53(1):79-90. doi: 10.1053/j.ajkd.2008.07.031. Epub 2008 Oct 18.</citation>
    <PMID>18930570</PMID>
  </reference>
  <reference>
    <citation>Bray BD, Boyd J, Daly C, Donaldson K, Doyle A, Fox JG, Innes A, Khan I, Peel RK, Severn A, Shilliday I, Simpson K, Stewart GA, Traynor J, Metcalfe W; Scottish Renal Registry. Vascular access type and risk of mortality in a national prospective cohort of haemodialysis patients. QJM. 2012 Nov;105(11):1097-103. doi: 10.1093/qjmed/hcs143. Epub 2012 Aug 20.</citation>
    <PMID>22908320</PMID>
  </reference>
  <reference>
    <citation>Vascular Access Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis. 2006 Jul;48 Suppl 1:S248-73.</citation>
    <PMID>16813991</PMID>
  </reference>
  <reference>
    <citation>Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, Tordoir J, Van Biesen W. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). NDT Plus. 2010 Jun;3(3):234-246. doi: 10.1093/ndtplus/sfq041.</citation>
    <PMID>30792802</PMID>
  </reference>
  <reference>
    <citation>Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 2001 Oct;60(4):1443-51.</citation>
    <PMID>11576358</PMID>
  </reference>
  <reference>
    <citation>Rayner HC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK; Dialysis Outcomes and Practice Patterns Study. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003 Jan;63(1):323-30.</citation>
    <PMID>12472799</PMID>
  </reference>
  <reference>
    <citation>Al-Jaishi AA, Oliver MJ, Thomas SM, Lok CE, Zhang JC, Garg AX, Kosa SD, Quinn RR, Moist LM. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014 Mar;63(3):464-78. doi: 10.1053/j.ajkd.2013.08.023. Epub 2013 Oct 30. Review.</citation>
    <PMID>24183112</PMID>
  </reference>
  <reference>
    <citation>Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg. 2012 Mar;55(3):849-55. doi: 10.1016/j.jvs.2011.07.095. Epub 2011 Nov 8. Review.</citation>
    <PMID>22070937</PMID>
  </reference>
  <reference>
    <citation>Bashar K, Conlon PJ, Kheirelseid EA, Aherne T, Walsh SR, Leahy A. Arteriovenous fistula in dialysis patients: Factors implicated in early and late AVF maturation failure. Surgeon. 2016 Oct;14(5):294-300. doi: 10.1016/j.surge.2016.02.001. Epub 2016 Mar 15. Review.</citation>
    <PMID>26988630</PMID>
  </reference>
  <reference>
    <citation>Brahmbhatt A, Remuzzi A, Franzoni M, Misra S. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int. 2016 Feb;89(2):303-316. doi: 10.1016/j.kint.2015.12.019. Review.</citation>
    <PMID>26806833</PMID>
  </reference>
  <reference>
    <citation>Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, Durante W. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):739-45. doi: 10.1161/ATVBAHA.107.160085. Epub 2008 Jan 17.</citation>
    <PMID>18202320</PMID>
  </reference>
  <reference>
    <citation>Shui S, Wang X, Chiang JY, Zheng L. Far-infrared therapy for cardiovascular, autoimmune, and other chronic health problems: A systematic review. Exp Biol Med (Maywood). 2015 Oct;240(10):1257-65. doi: 10.1177/1535370215573391. Epub 2015 Feb 25. Review. Retraction in: Exp Biol Med (Maywood). 2020 Aug;245(14):NP1.</citation>
    <PMID>25716016</PMID>
  </reference>
  <reference>
    <citation>Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013 Aug;62(2):304-11. doi: 10.1053/j.ajkd.2013.01.015. Epub 2013 Mar 6.</citation>
    <PMID>23474008</PMID>
  </reference>
  <reference>
    <citation>Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol. 2007 Mar;18(3):985-92. Epub 2007 Jan 31.</citation>
    <PMID>17267744</PMID>
  </reference>
  <reference>
    <citation>Lai CC, Fang HC, Mar GY, Liou JC, Tseng CJ, Liu CP. Post-angioplasty far infrared radiation therapy improves 1-year angioplasty-free hemodialysis access patency of recurrent obstructive lesions. Eur J Vasc Endovasc Surg. 2013 Dec;46(6):726-32. doi: 10.1016/j.ejvs.2013.09.018. Epub 2013 Sep 25.</citation>
    <PMID>24119468</PMID>
  </reference>
  <reference>
    <citation>McGrogan DG, Stringer S, Cockwell P, Jesky M, Ferro C, Maxwell AP, Inston NG. Arterial stiffness alone does not explain arteriovenous fistula outcomes. J Vasc Access. 2018 Jan;19(1):63-68. doi: 10.5301/jva.5000791.</citation>
    <PMID>29076519</PMID>
  </reference>
  <reference>
    <citation>Dember LM, Imrey PB, Duess MA, Hamburg NM, Larive B, Radeva M, Himmelfarb J, Kraiss LW, Kusek JW, Roy-Chaudhury P, Terry CM, Vazquez MA, Vongpatanasin W, Beck GJ, Vita JA; Hemodialysis Fistula Maturation Study GroupFeldmanH.FarberA.KaufmanJ.SternL.LeSageP.KivorkC.SoaresD.MalikovaM.AllonM.Yo ungC.TaylorM.WoodardL.MangadiK.MundaR.LeeT.AllowayR.El-KhatibM.CanaanT.PflumA.Thi ekenL.Campos-NaciffB.HuberT.BerceliS.JansenM.McCaslinG.TrahanY.DavidsonI.HwangC.L ightfootT.LivingstonC.ValenciaA.DolmatchB.FenvesA.HawkinsN.CheungA.KinikiniD.Trei manG.IhnatD.SarfatiM.LavasaniI.MaloneyM.SchlotfeldtL.BuchananC.ClarkC.CrawfordC.H amlettJ.KundzinsJ.ManahanL.WiseJ.GassmanJ.GreeneT.LiL. Vascular Function at Baseline in the Hemodialysis Fistula Maturation Study. J Am Heart Assoc. 2016 Jul 22;5(7). pii: e003227. doi: 10.1161/JAHA.116.003227.</citation>
    <PMID>27451463</PMID>
  </reference>
  <reference>
    <citation>Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol. 2006 Apr;17(4):1112-27. Review.</citation>
    <PMID>16565259</PMID>
  </reference>
  <reference>
    <citation>Lee T, Misra S. New Insights into Dialysis Vascular Access: Molecular Targets in Arteriovenous Fistula and Arteriovenous Graft Failure and Their Potential to Improve Vascular Access Outcomes. Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1504-12. doi: 10.2215/CJN.02030216. Epub 2016 Jul 11. Review.</citation>
    <PMID>27401527</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Kristine Lindhard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Infrared therapy</keyword>
  <keyword>Stenosis</keyword>
  <keyword>Maturation</keyword>
  <keyword>Arteriovenous fistula survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

